SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel
SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study.
Stay updated with breaking news from Andy Weymann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study.
Biotech company SolasCure has announced the results of its proof-of-concept phase 2 trial investigating its wound gel for chronic venous leg ulcer patients.
VirtaMed appoints Andy Weymann, MD, MBA, to Board of Directors VirtaMed, the world leader in medical simulation training, has added Andy Weymann to its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005306/en/ VirtaMed appoints Andy Weymann, MD, MBA, to Board of Directors (Photo: Business Wire) With more than 25 years of experience working in the medical device and biotech/pharma industry and as an orthopedic surgeon, Andy has extensive experience developing and launching products and a track record le...